1.25
price up icon5.93%   0.07
after-market Handel nachbörslich: 1.24 -0.01 -0.80%
loading
Schlusskurs vom Vortag:
$1.18
Offen:
$1.18
24-Stunden-Volumen:
145.36K
Relative Volume:
0.92
Marktkapitalisierung:
$83.04M
Einnahmen:
$391.70K
Nettoeinkommen (Verlust:
$-52.34M
KGV:
-1.7857
EPS:
-0.7
Netto-Cashflow:
$-45.92M
1W Leistung:
+5.04%
1M Leistung:
+8.70%
6M Leistung:
-59.15%
1J Leistung:
-64.99%
1-Tages-Spanne:
Value
$1.14
$1.25
1-Wochen-Bereich:
Value
$1.10
$1.25
52-Wochen-Spanne:
Value
$0.68
$4.10

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name
Firmenname
Ovid Therapeutics Inc
Name
Telefon
212-776-4381
Name
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Name
Mitarbeiter
40
Name
Twitter
@OvidRx
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
OVID's Discussions on Twitter

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-04-20 Herabstufung Cantor Fitzgerald Buy → Neutral
2021-03-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-12-02 Herabstufung Citigroup Buy → Neutral
2020-12-02 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-09-04 Eingeleitet RBC Capital Mkts Outperform
2018-04-20 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten

pulisher
Oct 31, 2024

Ovid Therapeutics to Host Investor Event - GlobeNewswire

Oct 31, 2024
pulisher
Oct 29, 2024

Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat

Oct 29, 2024
pulisher
Oct 18, 2024

Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace

Oct 18, 2024
pulisher
Oct 18, 2024

Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com

Oct 18, 2024
pulisher
Oct 18, 2024

Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com

Oct 18, 2024
pulisher
Oct 04, 2024

Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 04, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Oct 02, 2024

Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India

Oct 01, 2024
pulisher
Sep 30, 2024

Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada

Sep 30, 2024
pulisher
Sep 30, 2024

Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance

Sep 30, 2024
pulisher
Sep 30, 2024

Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat

Sep 30, 2024
pulisher
Sep 27, 2024

Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com

Sep 27, 2024
pulisher
Sep 26, 2024

Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan

Sep 26, 2024
pulisher
Sep 25, 2024

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sep 25, 2024
pulisher
Sep 24, 2024

Lombard Odier Asset Management USA Corp Has $236,000 Stock Position in V2X, Inc. (NYSE:VVX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Market Resilience: Vor Biopharma Inc (VOR) Finishes Weak at 0.83, Down -7.78 - The Dwinnex

Sep 24, 2024
pulisher
Sep 23, 2024

Lombard Odier Asset Management Europe Ltd Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

The Attractiveness of Investing In OmniAb Inc (OABI) is Growing - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Oxford Biomedica Sees Robust Growth in 2024 - TipRanks

Sep 23, 2024
pulisher
Sep 21, 2024

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Victory Capital Management Inc. Has $991,000 Holdings in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Ovid Therapeutics (NASDAQ:OVID) Shares Cross Below Fifty Day Moving Average of $1.06 - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

After epilepsy setback, Ovid charges confidently ahead in CNS - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Q3 2025 EPS Estimates for ModivCare Inc. (NASDAQ:MODV) Reduced by Analyst - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Victory Capital Management Inc. Increases Position in OneMain Holdings, Inc. (NYSE:OMF) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Ovid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06 - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Checking in on OmniAb Inc (OABI) after recent insiders movement - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Is OmniAb Inc (OABI) positioned for future growth? - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Federated Hermes Inc. Purchases 5,323 Shares of Ovintiv Inc. (NYSE:OVV) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Box announces pricing of $400M debt offering via issuance of convertible senior notes due 2029 - MSN

Sep 18, 2024
pulisher
Sep 18, 2024

Oxford Biomedica Emerges as OXB with Global Vision - TipRanks

Sep 18, 2024
pulisher
Sep 17, 2024

Recent Insider Activity Could Benefit Olo Inc (OLO) - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

ModivCare (NASDAQ:MODV) PT Lowered to $19.00 - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Gaining Ground: Outset Medical Inc (OM) Closes Lower at 0.52, Down -1.34 - The Dwinnex

Sep 17, 2024
pulisher
Sep 16, 2024

Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – OM - ForexTV.com

Sep 16, 2024
pulisher
Sep 16, 2024

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology

Sep 16, 2024
pulisher
Sep 13, 2024

FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia

Sep 13, 2024
pulisher
Sep 13, 2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - Citizentribune

Sep 13, 2024
pulisher
Sep 12, 2024

Ovid Therapeutics names new President and COO - Investing.com India

Sep 12, 2024
pulisher
Sep 12, 2024

Moderna Pulls Back on R&D and Delays Timeline for Profitability. The Stock Tumbles. - MSN

Sep 12, 2024
pulisher
Sep 12, 2024

Moderna slashes research spending, trims pipeline as it looks to regain footing - MSN

Sep 12, 2024

Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):